Equities

Praxis Precision Medicines Inc

PRAX:NSQ

Praxis Precision Medicines Inc

Actions
  • Price (USD)77.88
  • Today's Change2.53 / 3.35%
  • Shares traded317.65k
  • 1 Year change+419.17%
  • Beta2.6841
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform5
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Praxis Precision Medicines Inc have a median target of 148.00, with a high estimate of 270.00 and a low estimate of 57.00. The median estimate represents a 90.05% increase from the last price of 77.88.
High246.7%270.00
Med90.0%148.00
Low-26.8%57.00

Earnings history & estimates in USD

On Nov 06, 2024, Praxis Precision Medicines Inc reported 3rd quarter 2024 losses of -2.75 per share.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate-6.23%
Praxis Precision Medicines Inc reported annual 2023 losses of -18.69 per share on Mar 05, 2024.
Average growth rate+35.08%
More ▼

Revenue history & estimates in USD

Praxis Precision Medicines Inc had 3rd quarter 2024 revenues of 302.00k. This bettered the 296.00k consensus of the 10 analysts covering the company. This was 55.78% below the prior year's 3rd quarter results.
Average growth rate-9.71%
Praxis Precision Medicines Inc had revenues for the full year 2023 of 2.45m.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.